CoChat

(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism

Open access

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

Background: Although recent studies provide insight into the molecular mechanisms of the effects of ketamine, the antidepressant mechanism of ketamine enantiomers and their metabolites is not fully understood. In view of the involvement of mechanisms other than the N-methyl-D-aspartate receptor in ketamine’s action, we investigated the effects of (R)-ketamine, (S)-ketamine, (R)-norketamine [(R)-NK], (S)-NK, (2R,6R)-hydroxynorketamine [(2R,6R)-HNK], and (2S,6S)-HNK on monoaminergic neurotransmission in the prefrontal cortex of mice. Methods: The extracellular monoamine levels in the prefrontal cortex were measured by in vivo microdialysis. Results: (R)-Ketamine and (S)-ketamine acutely increased serotonin release in a dose-dependent manner, and the effect of (R)-ketamine was greater than that of (S)-ketamine. In contrast, (S)-ketamine caused a robust increase in dopamine release compared with (R)-ketamine. Both ketamine enantiomers increased noradrenaline release, but these effects did not differ. (2R,6R)-HNK caused a slight but significant increase in serotonin and noradrenaline but not dopamine release. (S)-NK increased dopamine and noradrenaline but not serotonin release. Differential effects between (R)-ketamine and (S)-ketamine were also observed in a lipopolysaccharide-induced model of depression. An α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonist, 2,3-dioxo-6-nitro-1,2,3,4- tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX), attenuated (S)-ketamine-induced, but not (R)-ketamine-induced serotonin release, whereas NBQX blocked dopamine release induced by both enantiomers. Local application of (R)-ketamine into the prefrontal cortex caused a greater increase in prefrontal serotonin release than that of (S)-ketamine. Conclusions: (R)-Ketamine strongly activates the prefrontal serotonergic system through an AMPA receptor-independent mechanism. (S)-Ketamine-induced serotonin and dopamine release was AMPA receptor-dependent. These findings provide a neurochemical basis for the underlying pharmacological differences between ketamine enantiomers and their metabolites.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyz041

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The effects of (R)-ketamine, (S)-ketamine, and their metabolites on extracellular serotonin (5-HT) (A), dopamine (DA) (B), and noradrenaline (NA) (C) levels in the prefrontal cortex (PFC) of mice. (R)-ketamine (10, 20 mg/kg), (S)-ketamine (10, 20 mg/kg), (R)-norketamine [(R)-NK] (20 mg/kg), (S)-NK (20 mg/kg), (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] (20 mg/kg), (2S,6S)-HNK (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the saline-treated mice at each time point.
Figure 1. The effects of (R)-ketamine, (S)-ketamine, and their metabolites on extracellular serotonin (5-HT) (A), dopamine (DA) (B), and noradrenaline (NA) (C) levels in the prefrontal cortex (PFC) of mice. (R)-ketamine (10, 20 mg/kg), (S)-ketamine (10, 20 mg/kg), (R)-norketamine [(R)-NK] (20 mg/kg), (S)-NK (20 mg/kg), (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] (20 mg/kg), (2S,6S)-HNK (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the saline-treated mice at each time point.CC BY-NC · PubMed Central
Figure 2. The effects of (R)-ketamine and (S)-ketamine on extracellular monoamine levels in the prefrontal cortex (PFC) of lipopolysaccharide (LPS)-treated mice. Mice were i.p. injected with LPS (0.5 mg/kg) 24 hours before the experiment. (R)-Ketamine (20 mg/kg), (S)-ketamine (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with saline-treated mice at each time point. #P < .05, ##P < .01, compared with (S)-ketamine-treated mice at each time point.
Figure 2. The effects of (R)-ketamine and (S)-ketamine on extracellular monoamine levels in the prefrontal cortex (PFC) of lipopolysaccharide (LPS)-treated mice. Mice were i.p. injected with LPS (0.5 mg/kg) 24 hours before the experiment. (R)-Ketamine (20 mg/kg), (S)-ketamine (20 mg/kg), or saline was i.p. injected at 0 minutes (arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with saline-treated mice at each time point. #P < .05, ##P < .01, compared with (S)-ketamine-treated mice at each time point.CC BY-NC · PubMed Central
Figure 3. The effects of NBQX on (R)-ketamine- and (S)-ketamine-induced monoamine release in the prefrontal cortex (PFC) of mice. (R)-Ketamine (20 mg/kg) (A) or (S)-ketamine (20 mg/kg) (B) was i.p. injected at 0 minutes (solid arrow). NBQX (10 mg/kg) or vehicle was s.c. injected 20 minutes before ketamine treatment (dotted arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with vehicle-pretreated mice at each time point.
Figure 3. The effects of NBQX on (R)-ketamine- and (S)-ketamine-induced monoamine release in the prefrontal cortex (PFC) of mice. (R)-Ketamine (20 mg/kg) (A) or (S)-ketamine (20 mg/kg) (B) was i.p. injected at 0 minutes (solid arrow). NBQX (10 mg/kg) or vehicle was s.c. injected 20 minutes before ketamine treatment (dotted arrow). Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with vehicle-pretreated mice at each time point.CC BY-NC · PubMed Central
Figure 4. The effects of local application of (R)-ketamine and (S)-ketamine on extracellular monoamine levels in the prefrontal cortex (PFC) of mice. (R)-Ketamine (50 µM), (S)-ketamine (50 µM), or vehicle was perfused into the PFC via the dialysis probe for the time indicated by the horizontal bar. Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the vehicle-treated mice at each time point. #P < .05, ##P < .01, compared with the (S)-ketamine-treated mice at each time point.
Figure 4. The effects of local application of (R)-ketamine and (S)-ketamine on extracellular monoamine levels in the prefrontal cortex (PFC) of mice. (R)-Ketamine (50 µM), (S)-ketamine (50 µM), or vehicle was perfused into the PFC via the dialysis probe for the time indicated by the horizontal bar. Results are expressed as the mean ± SEM of 5 mice per group. *P < .05, **P < .01, compared with the vehicle-treated mice at each time point. #P < .05, ##P < .01, compared with the (S)-ketamine-treated mice at each time point.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 92

Metadata

Authors
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., Nakazawa, T., Nakagawa, S., Hashimoto, K., & Hashimoto, H.
Affiliations
  • The University of Osaka (JP)
  • Kanazawa University (JP)
Corresponding author
Ago, Yukio
Venue
International Journal of Neuropsychopharmacology
Published
2019-07-21
Volume
22
Issue
10
Pages
665-674
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2966617845
Cited by
92
References
71
Citations by year
2026: 10 · 2025: 11 · 2024: 11 · 2023: 16 · 2022: 15 · 2021: 15 · 2020: 13 · 2019: 1
FWCI
6.81
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Japan Society for the Promotion of Science (JP16K08268, JP17K19488, JP17H03989)
  • Ministry of Education, Culture, Sports, Science and Technology (JP18H05416, JP19dm0107122, JP19dm0207061, JP19dm0107119)
  • Takeda Science Foundation
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
ketamine enantiomers, (R)-ketamine, esketamine, ketamine metabolites, norketamine, hydroxynorketamine, serotonin release, dopamine release, noradrenaline release, prefrontal cortex, AMPA receptors, NBQX, antidepressant mechanism, lipopolysaccharide-induced depression, monoaminergic neurotransmission
MeSH terms
Animals, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Ketamine, Lipopolysaccharides, Male, Microinjections, Norepinephrine, Quinoxalines, Serotonin, Stereoisomerism, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism. https://app.cochat.ai/papers/10.1093/ijnp/pyz041
The paper
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., Nakazawa, T., Nakagawa, S., Hashimoto, K., & Hashimoto, H. (2019). (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz041

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.